DOCSLIB.ORG

MAKING SENSE of CORONAVIRUS MUTATIONS Different SARS-Cov-2 Strains Haven’T Yet Had a Major Impact on the Course of the Pandemic — but They Might in Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MAKING SENSE of CORONAVIRUS MUTATIONS Different SARS-Cov-2 Strains Haven’T Yet Had a Major Impact on the Course of the Pandemic — but They Might in Future Feature SOURCE: STRUCTURAL DATA FROM K. SHEN & J. LUBAN K. SHEN FROM DATA STRUCTURAL SOURCE: The spike protein of SARS-CoV-2 has a common mutation (circled) that seems to shift the protein from a closed (left) to an open (right) form. MAKING SENSE OF CORONAVIRUS MUTATIONS Different SARS-CoV-2 strains haven’t yet had a major impact on the course of the pandemic — but they might in future. By Ewen Callaway hen COVID-19 spread around started scouring thousands of coronavirus In April, Korber, Montefiori and others the globe this year, David genetic sequences for mutations that might warned in a preprint posted to the bioRxiv Montefiori wondered how the have changed the virus’s properties as it made server that “D614G is increasing in frequency deadly virus behind the pan- its way around the world. at an alarming rate”1. It had rapidly become demic might be changing as it Compared with HIV, SARS-CoV-2 is chang- the dominant SARS-CoV-2 lineage in Europe passed from person to person. ing much more slowly as it spreads. But one and had then taken hold in the United States, Montefiori is a virologist who mutation stood out to Korber. It was in the Canada and Australia. D614G represented a has spent much of his career gene encoding the spike protein, which helps “more transmissible form of SARS-CoV-2”, Wstudying how chance mutations in HIV help it virus particles to penetrate cells. Korber saw the paper declared, one that had emerged as to evade the immune system. The same thing the mutation appearing again and again in a product of natural selection. might happen with SARS-CoV-2, he thought. samples from people with COVID-19. At the These assertions dismayed many scientists. In March, Montefiori, who directs an 614th amino-acid position of the spike pro- It wasn’t clear that the D614G viral lineage was AIDS-vaccine research laboratory at Duke tein, the amino acid aspartate (D, in biochem- more transmissible, or that its rise indicated University in Durham, North Carolina, con- ical shorthand) was regularly being replaced anything unusual, they said. But alarm spread tacted Bette Korber, an expert in HIV evolution by glycine (G) because of a copying fault fast across the media. Although many news and a long-time collaborator. Korber, a compu- that altered a single nucleotide in the virus’s stories included researchers’ caveats, some tational biologist at the Los Alamos National 29,903-letter RNA code. Virologists were call- headlines declared that the virus was mutat- Laboratory (LANL) in New Mexico, had already ing it the D614G mutation. ing to become more dangerous. In retrospect, 174 | Nature | Vol 585 | 10 September 2020 | Corrected 16 September ©2020 Spri nger Nature Li mited. All rights reserved. ©2020 Spri nger Nature Li mited. All rights reserved. 2 mm Montefiori says he and his colleagues regret GLOBAL SPREAD even potentially beneficial mutations might describing the variant’s rise as “alarming”. The By the end of June, the D614G mutation was found not flourish. “As far as the virus is concerned, word was scrubbed from the peer-reviewed in almost all SARS-CoV-2 samples worldwide. every single person that it comes to is a good 2 3 mm version of the paper, published in Cell in July . 1.0 piece of meat,” says William Hanage, an epi- The work sparked a frenzy of interest in demiologist at the Harvard T. H. Chan School 3 mm D614G. Even those who were sceptical that of Public Health in Boston, Massachusetts. 0.8 the mutation had changed the virus’s prop- “There’s no selection to be doing it any better.” erties agreed that it was intriguing, because of its meteoric rise and ubiquity. For months, 0.6 Faster spread? that lineage has been found in almost all When Korber saw the rapid spread of D614G, sequenced samples of SARS-CoV-2 (see ‘Global she thought she might have found an example 0.4 spread’). “This variant now is the pandemic. of meaningful natural selection. The muta- As a result, its properties matter,” wrote of D614G* Frequency tion caught her eye because of its position in Nathan Grubaugh, a viral epidemiologist at 0.2 the spike protein, which is a major target for the Yale School of Public Health in New Haven, ‘neutralizing’ antibodies that bind to the virus Connecticut, and two colleagues in a Cell essay and render it non-infectious. And viruses with 3 0 on Korber and Montefiori’s findings . Jan Feb Mar Apr May Jun the mutation were also rising in frequency in So far, the upshot of this work is less clear 2020 more than one part of the world. *Number of samples = 52,292 SOURCE: REF. 8 REF. SOURCE: than Montefiori and Korber’s preprint sug- D614G was first spotted in viruses collected gested. Some experiments suggest that mistakes. A typical SARS-CoV-2 virus accu- in China and Germany in late January; most viruses carrying the variant infect cells more mulates only two single-letter mutations per scientists suspect the mutation arose in China. easily. Other work has revealed possible good month in its genome — a rate of change about It’s now almost always accompanied by three news: the variant might mean that vaccines half that of influenza and one-quarter that of mutations in other parts of the SARS-CoV-2 can target SARS-CoV-2 more easily. But many HIV, says Emma Hodcroft, a molecular epidemi- genome — possible evidence that most D614G scientists say there remains no solid proof that ologist at the University of Basel, Switzerland. viruses share a common ancestor. D614G has a significant effect on the spread of Other genome data have emphasized D614G’s rapid rise in Europe drew Korber’s the virus, or that a process of natural selection this stability — more than 90,000 isolates attention. Before March — when much of the explains its rise. “The jury’s out,” says Timothy have been sequenced and made public (see continent went into lockdown — both unmu- Sheahan, a coronavirologist at the University www.gisaid.org). Two SARS-CoV-2 viruses tated ‘D’ viruses and mutated ‘G’ viruses were of North Carolina at Chapel Hill. “This muta- collected from anywhere in the world differ by present, with D viruses prevalent in most of tion might mean something, or it might not.” an average of just 10 RNA letters out of 29,903, the western European countries that geneti- Researchers still have more questions says Lucy Van Dorp, a computational geneticist cists sampled at the time. In March, G viruses than answers about coronavirus mutations, at University College London, who is tracking rose in frequency across the continent, and by and no one has yet found any change in the differences for signs that they confer an April they were dominant, reported Korber, SARS-CoV-2 that should raise public-health evolutionary advantage. Montefiori and their team1,2. concerns, Sheahan, Grubaugh and others Despite the virus’s sluggish mutation rate, But natural selection in favour of G viruses say. But studying mutations in detail could researchers have catalogued more than 12,000 isn’t the only, or even the most likely, explana- be important for controlling the pandemic. mutations in SARS-CoV-2 genomes. But scien- tion for this pattern. The European dominance It might also help to pre-empt the most tists can spot mutations faster than they can of G variants could be simply down to chance worrying of mutations: those that could help — if, for instance, the mutation happened to the virus to evade immune systems, vaccines “This variant now is the be slightly more common in the viruses that or antibody therapies. arrived in Europe. A small number of indi- pandemic. As a result, its viduals seem to be responsible for most of Slow change properties matter.” the virus’s spread, and an early, chance tilt in Soon after SARS-CoV-2 was detected in China, favour of G viruses could explain the lineage’s researchers began analysing viral samples and apparent takeover now. Such ‘founder effects’ posting the genetic codes online. Mutations — make sense of them. Many mutations will are common in viruses, especially when they most of them single-letter alterations between have no consequence for the virus’s ability spread unchecked, as SARS-CoV-2 did in much viruses from different people — allowed to spread or cause disease, because they do of Europe until mid- to late March. researchers to track the spread by linking not alter the shape of a protein, whereas those Korber and her colleagues tried to rule out closely related viruses, and to estimate when mutations that do change proteins are more a founder effect, by showing in their April pre- SARS-CoV-2 started infecting humans. likely to harm the virus than improve it (see print1 that D614G rose to dominance quickly Viruses that encode their genome in RNA, ‘A catalogue of coronavirus mutations’). “It’s in Canada, Australia and parts of the United such as SARS-CoV-2, HIV and influenza, tend much easier to break something than it is to States (an exception was Iceland, where to pick up mutations quickly as they are cop- fix it,” says Hodcroft, who is part of Nextstrain G viruses present early in its outbreak were ied inside their hosts, because enzymes that (https://nextstrain.org), an effort to analyse overtaken by D viruses). Analysing hospitali- copy RNA are prone to making errors. After SARS-CoV-2 genomes in real time. zation data from Sheffield, UK, the team found the severe acute respiratory syndrome (SARS) Many researchers suspect that if a mutation no evidence that viruses carrying the mutation virus began circulating in humans, for instance, did help the virus to spread faster, it probably made people any sicker.
Load more

Recommended publications
  • Our Immune System, Vaccines, and Vaccine Strategies for AIDS and COVID-19
    Our Immune System, Vaccines, and Vaccine Strategies for AIDS and COVID-19 Dr. Bette Korber Los Alamos National Laboratory Constantly vigilant, our immune system recognizes and controls infections to protect us from disease. Furthermore, we have a capacity for immunological memory, which enables our immune system to “remember” a pathogen we have encountered in the past, and to make a more rapid and vigorous defensive response should we encounter that same disease again. Vaccines tap into this natural capacity for immunological memory. I’ll briefly review our ongoing work at Los Alamos National Laboratory to contribute to global vaccine efforts for HIV-1 and COVID-19. The rapid evolution and extraordinary diversity of HIV provides particular challenges for developing an AIDS vaccine, and our work focuses on strategies to contend with that diversity. By contrast, SARS-CoV-2, the virus that causes COVID-19, has evolved very slowly during the pandemic, although even this limited diversity can be important. We are tracking emerging viral diversity to help design appropriate reagents to ensure that COVID-19 vaccines and therapeutics currently under development will remain relevant over the coming year. Using our tracking tools, last April we identified a SARS-CoV-2 variant that appeared to be more transmissible than the original form. This viral variant was subsequently shown to be more infectious experimentally, and has now become the globally dominant form of the virus. Bio Dr. Bette Korber is a Laboratory Fellow at the Los Alamos National Laboratory in the Theoretical Biology and Biophysics Group. Her work focuses on viral evolution, the human immune response to infection, and vaccine design.
    [Show full text]
  • Spread of a SARS-Cov-2 Variant Through Europe in the Summer of 2020
    Article Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 https://doi.org/10.1038/s41586-021-03677-y Emma B. Hodcroft1,2,3 ✉, Moira Zuber1, Sarah Nadeau2,4, Timothy G. Vaughan2,4, Katharine H. D. Crawford5,6,7, Christian L. Althaus3, Martina L. Reichmuth3, John E. Bowen8, Received: 25 November 2020 Alexandra C. Walls8, Davide Corti9, Jesse D. Bloom5,6,10, David Veesler8, David Mateo11, Accepted: 28 May 2021 Alberto Hernando11, Iñaki Comas12,13, Fernando González-Candelas13,14, SeqCOVID-SPAIN consortium*, Tanja Stadler2,4,92 & Richard A. Neher1,2,92 ✉ Published online: 7 June 2021 Check for updates Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3–5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identifed in Spain in early summer 2020 and subsequently spread across Europe. We fnd no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of efective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local eforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings.
    [Show full text]
  • Developing a Single-Cycle Infectious System to Study an ERV-K Retroviral Envelope
    Developing a Single-Cycle Infectious System to Study an ERV-K Retroviral Envelope Author: Rana Elias Akleh Persistent link: http://hdl.handle.net/2345/bc-ir:107695 This work is posted on eScholarship@BC, Boston College University Libraries. Boston College Electronic Thesis or Dissertation, 2017 Copyright is held by the author. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (http:// creativecommons.org/licenses/by-nc-sa/4.0). Developing a Single-Cycle Infectious System to Study an ERV-K Retroviral Envelope Rana Elias Akleh A thesis submitted to the faculty of the department of Biology in partial fulfillment of the requirements for the degree of Master of Science Boston College Morrissey College of Arts and Sciences Graduate School September 2017 © 2017 Rana Elias Akleh Developing a Single-Cycle Infectious System to Study an ERV-K Retroviral Envelope Rana Elias Akleh Advisor: Welkin Johnson, Ph.D. Endogenous Retroviruses (ERVs) are “fossilized” retroviruses of a once exogenous retrovirus located in the genome of extant vertebrates. Retroviral infection results in a provirus integration into the host genome. An infection of a germline cell could lead to the provirus potentially being inherited by the offspring of the infected individual. Once in the genome, the provirus becomes subject to evolutionary processes and can become either lost or fixed in a population, remaining as “fossils” long after the exogenous retrovirus has gone extinct23. Notably, 8% of the human genome consists of ERVs30. Human Endogenous Retrovirus Type K (HERV-K)(HML-2) family is of particular interest. HERV-K integrations are as old as 30-35 million years, endogenizing before the separation of humans and Old World Monkeys.
    [Show full text]
  • Researchers Unveil New Monkey Model for HIV 2 March 2009
    Researchers unveil new monkey model for HIV 2 March 2009 By altering just one gene in HIV-1, scientists have evolving genes, APOBEC3 and TRIM5, which succeeded in infecting pig-tailed macaque produce unusual classes of defensive proteins with monkeys with a human version of the virus that distinctive capabilities to fight retroviruses such as has until now been impossible to study directly in HIV. These genes, shared by humans and their animals. The new strain of HIV has already been simian forebears, have evolved mutations specific used to demonstrate one method for preventing to each species' unique history of retroviral battles. infection and, with a little tweaking, could be a In most simians, the APOBEC3 and TRIM5 valuable model for vetting vaccine candidates. proteins actually kill HIV on sight, making it impossible for researchers to study the virus in an A team of researchers led by Paul Bieniasz and animal model. Instead, they have studied HIV's Theodora Hatziioannou at The Rockefeller cousin, simian immunodeficiency virus (SIV), which University showed that two pig-tailed macaques, causes an AIDS-like disease in certain monkey given a common antiretroviral treatment one week species. But SIV shares only about half of its amino before and one week after being exposed to the acid sequence with HIV, making it a very imperfect newly engineered HIV, had no signs of infection. substitute for testing anti-HIV drugs and vaccines. "We're not saying we can save the world with Several labs have engineered hybrids called SHIVs antiretroviral pills. But this model will allow us to — SIVs that contain pieces of HIV DNA — but these start studying the best way to administer have problematic differences, too.
    [Show full text]
  • Local Ceremonies to Honor the Team Were Held This Spring in Santa Fe
    ReflectionsLos Alamos National Laboratory Vol. 3, No. 5 • June 1998 … see pages 6 and 7 A Department of Energy/University of California Laboratory Reflections Inside this issue … Safety: month-long emphasis, Cover photo illustration by Edwin Vigil year-long concern Immunologist devotes life’s work to AIDS research . Page 3 June is National Safety Month, and a number of activities promoting safety are taking place at work sites, schools and other Making the Lab safer . Page 4 institutions across the country. No doubt there will be lots of Lab would rather pamphlets handed out, advice given, statistics recited and presen- give it away . Page 5 tations made during the monthly observance. But if calling attention to safety Nonproliferation . Pages 6 and 7 saves just one life or prevents just one person from being injured, it will be well worth the effort. People . Pages 8 and 9 Here at the Lab, Safety Month will be observed in July (see Page 4) as it was last Just for fun . Page 11 year. Still, it doesn’t hurt to get in the spirit of thinking about safety a month in Spotlight: advance. Actually, safety is something we should think about all the time, on or Really tough ladies . Page 12 off the job. This was noted recently by an employee in a Daily Newsbulletin letter to the editor (“Safe-living people vs. safely-operating employees,” April 21). The employee said he practices safety at work because he is a safety-conscious person all the time. “I think safety consciousness only gets internalized and personalized when it is not limited to the workplace,” he wrote.
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]
  • Final Scientific Programme
    Final Scientific Programme Day 1 – Thursday, April 29 Arrival of conferees, registration, get-together party Session 1 Welcoming and Opening Remarks Chairman: Jan Svoboda 04:30 - 05:00 pm Jan Svoboda, Institute of Molecular Genetics, Prague Background and perspectives David Baltimore, California Institute of Technology, Pasadena 05:00 - 06:00 pm Keynote lecture 06:00 pm Welcome reception Day 2 – Friday, April 30 Session 2 Action at the Cell Surface Chairmen: John A.T. Young, Benjamin K. Chen 08:30 - 09:00 am John A.T. Young, Salk Institute, La Jolla Cellular factor involvement in retroviral replication 09:00 - 09:30 am Benjamin K. Chen, Mount Sinai School of Medicine, New York Spread of HIV through T cell virological synapses 09:30 - 09:45 am Paul Jolicoeur, Clinical Research Institute of Montreal Pathogenesis of HIV-1 Nef in thymocytes 09:45 - 10:00 am Michaela Rumlová, Institute of Organic Chemistry and Biochemistry, Prague Analysis of N-terminus of NC protein of M-PMV: its role in the particle assembly 10:00 - 10:30 am Coffee break Session 3 Identification of Essential Host Cell Factors Chairmen: Stephen P. Goff, Alan N. Engelmam 10:30 - 11:00 am Stephen P. Goff, Columbia University, New York HIV-1 Interactions with host proteins 11:00 - 11:30 am Alan N. Engelmam, Dana-Farber Cancer Institute, Boston HIV-1 preintegration complex function and host cell factors 11:30 - 11:45 am Peter Cherepanov, Imperial College London Structural basis for retroviral pre-integration complex assembly and strand transfer inhibitor action 11:45 - 12:00 am C.
    [Show full text]
  • Evolution and Origins of SARS- Cov-2 and Related Coronaviruses Introduction to Evolution and Scientific Inquiry Spring 2020, Dr
    Evolution and origins of SARS- CoV-2 and related coronaviruses Introduction to Evolution and Scientific Inquiry Spring 2020, Dr. Spielman Zoonosis Image from April 2019 • Virus that normally infects one animal species infects a NEW/DIFFERENT species • Sometimes from a new mutation • Sometimes from an existing mutation • Sometimes no mutation at all – it just can infect multiple species Viruses bind host receptors or other cell-surface proteins https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000217 ACE2: Angiotension-converting enzyme 2 • ACE constricts blood flow • ACE inhibitors relax veins to improve blood flow. BRIEF COMMUNICATION Used to treat… https://doi.org/10.1038/s41591-020-0868-6 • Heart disease • Angiotension SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate • Diabetes immune genes • Migraines Waradon Sungnak! !1 , Ni Huang1, Christophe Bécavin! !2, Marijn Berg3,4, Rachel Queen5, Monika Litvinukova1,6, Carlos Talavera-López1, Henrike Maatz6, Daniel Reichart7, • Chronic kidney diseases Fotios Sampaziotis! !8,9,10, Kaylee B. Worlock11, Masahiro Yoshida! !11, Josephine L. Barnes11 and HCA Lung Biological Network* We investigated SARS-CoV-2 potential tropism by survey- associated with SARS-CoV-2 pathogenesis at cellular resolution, inghttps:// expressionwww.nature.com of viral entry-associated/articles/s41591 genes in single-cell using-020 single-cell-0868 RNA- 6sequencing (scRNA-seq) datasets from healthy RNA-sequencing data from multiple tissues from healthy donors generated by the Human Cell Atlas consortium and other human donors. We co-detected these transcripts in specific resources to inform and prioritize the use of precious, limited clinical respiratory, corneal and intestinal epithelial cells, potentially material that is becoming available from COVID-19 patients.
    [Show full text]
  • Regulation of Murine Class I Genes by Interferons Is Controlled by Regions
    Proc. Nati. Acad. Sci. USA Vol. 84, pp. 3380-3384, May 1987 Immunology Regulation of murine class I genes by interferons is controlled by regions located both 5' and 3' to the transcription initiation site (interferon action/transplantation antigens/gene regulation) BETTE KORBER, LEROY HOOD, AND IWONA STROYNOWSKI Division of Biology, California Institute of Technology, Pasadena, CA 91125 Contributed by Leroy Hood, January 7, 1987 ABSTRACT Interferons regulate the expression of a large initiation site are independently involved in IFN-a and IFN-y number of mammalian genes, including the major histocom- regulation of murine class I genes and that the level of patibility antigen genes. To investigate the mechanisms in- induction controlled by the promoter region constitutes only volved in interferon action, we have analyzed the ability of a minor portion of the response in L cells. In addition, we murine H-2Ld and H-2Dd DNA sequences to control the present results suggesting that the response to IFN-y and -a responses to interferon. The results indicate that interferon may have different sequence requirements in the promoter regulation of class I gene expression is complex and involves at region. least two mechanisms that are dependent on class I sequences located upstream and downstream to the transcription initia- tion site. In transfected mouse L cells, both of these regions are MATERIALS AND METHODS required for full enhancement of class I gene expression, with DNA Constructs, Enzymes, and Reagents. Class I genes and the major portion of the response controlled by the sequences their derivatives were subcloned from BALB/c cosmid and located 3' to the transcription initiation site.
    [Show full text]
  • BETTE KORBER for the Degree of Doctor of Philosophy Chemical
    REGULATION OF GLASS I GENES BY INTERFERONS Thesis by BETTE KORBER In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Division of Chemistry and Chemical Engineering California Institute of Technology Pasadena, California 1988 (submitted May 17, 1988) 11 This thesis is dedicated to my shelter and my storm, James Theiler. Ill Through the years, a man peoples a space with images of provinces, kingdoms, mountains, bays, ships, islands, fishes, rooms, tools, stars, horses, and people. Shortly before his death, he discovers that the patient labyrinth of lines traces the image of his own face. Beyond my anxiety, beyond this writing, the universe waits, inexhaustible, inviting. — Jorge Luis Borges You see, one thing is, I can live with doubt and uncertainty and not knowing. I think it is much more interesting to live not knowing than to have answers which might be wrong. I have approximate answers and possible beliefs and different degrees of certainty about different things... I don’t feel frightened by not knowing things, by being lost in a mysterious universe without having any purpose, which is the way it really is, so far as I can tell... I don’t feel frightened. — Richard P. Feynman Don’t be blue, be determined. — Leroy Hood iV TABLE OF COHTEHTS Page Acknowledgements...........................................................................................................................................................'v Abstract...............................................................................................................................................................................
    [Show full text]
  • Molecular Ecology and Natural History of Simian Foamy Virus Infection in Wild-Living Chimpanzees
    Molecular Ecology and Natural History of Simian Foamy Virus Infection in Wild-Living Chimpanzees Weimin Liu1, Michael Worobey2, Yingying Li1, Brandon F. Keele1, Frederic Bibollet-Ruche1, Yuanyuan Guo1, Paul A. Goepfert1, Mario L. Santiago3, Jean-Bosco N. Ndjango4, Cecile Neel5,6, Stephen L. Clifford7, Crickette Sanz8, Shadrack Kamenya9, Michael L. Wilson10, Anne E. Pusey11, Nicole Gross-Camp12, Christophe Boesch8, Vince Smith13, Koichiro Zamma14, Michael A. Huffman15, John C. Mitani16, David P. Watts17, Martine Peeters5, George M. Shaw1, William M. Switzer18, Paul M. Sharp19, Beatrice H. Hahn1* 1 Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 2 University of Arizona, Tucson, Arizona, United States of America, 3 Gladstone Institute for Virology and Immunology, University of California at San Francisco, San Francisco, California, United States of America, 4 Faculties of Sciences, University of Kisangani, Democratic Republic of Congo, 5 Institut de Recherche pour le De´veloppement (IRD) and University of Montpellier 1, Montpellier, France, 6 Projet Prevention du Sida ou Cameroun (PRESICA), Yaounde´, Cameroun, 7 Centre International de Recherches Medicales de Franceville (CIRMF), Franceville, Gabon, 8 Max-Planck Institute for Evolutionary Anthropology, Leipzig, Germany, 9 Gombe Stream Research Centre, The Jane Goodall Institute, Tanzania, 10 Department of Anthropology, University of Minnesota, Minneapolis, Minnesota, United States of America, 11 Jane Goodall Institute’s
    [Show full text]
  • HIV Vaccine-Research Team Shifts to SARS-Cov-2
    HIV vaccine-research team shifts to SARS-CoV-2 May 7, 2020 Building on previous work designing an experimental HIV vaccine being tested in two human vaccine efficacy trials, the Los Alamos National Laboratory HIV team is now deploying its expertise in genetic databases and bioinformatics against the novel coronavirus SARS-CoV-2, the virus that causes the COVID-19 disease. Three main thrusts are underway from the HIV team: developing a T-cell response vaccine approach, tracking the origin of the pathogen, and building a robust bioinformatics pipeline to track the virus’s evolution. While this work focuses on attacking the virus itself, other bioinformatics and modeling efforts across the Laboratory aim at predicting disease spread to support decision making by government and health agencies. Developing a T-cell response vaccine approach Bette Korber, a computational biologist and the driving force behind the “mosaic” vaccine concept for HIV, together with fellow scientists Will Fischer and Sandrasegaram Gnanakaran, is shifting her attention from HIV, ebola, and influenza vaccines to developing a T-cell based vaccine design for the SARS CoV-2 coronavirus. Traditional antibody vaccines are primarily intended to reduce rates of infection. Korber says they hope that vaccine-elicited T-cell responses could help ameliorate disease severity if people do get infected, and so this approach could be used to complement antibody-based vaccines. Korber and the HIV team members are in the Laboratory’s Theoretical Biology and Biophysics group. Tracking the origin of the pathogen Elena Giorgi, also of the Theoretical Biology and Biophysics group, recently published a pre-print paper on the origins of the virus,“Emergence of SARS-CoV-2 through Recombination and Strong Purifying Selection.” “Our team demonstrated, by looking at the genetic sequence of the virus and comparing it to other known coronaviruses, that it originated from animals,” said Giorgi.
    [Show full text]